key: cord-0291899-s6v28oy3
authors: Mansilla, C.; Herrera, C. A.; Boeira, L.; Yearwood, A.; Lopez, A. S.; Colunga-Lozano, L. E.; Brocard, E.; Villacres, T.; Velez, M.; Di Paolantonio, G.; Reveiz, L.
title: Characterising COVID-19 empirical research production in Latin America and the Caribbean: a scoping review
date: 2021-08-05
journal: nan
DOI: 10.1101/2021.07.30.21261386
sha: 1e8aa9dcea27acd945e3bdc3b1643cca7c3dccf2
doc_id: 291899
cord_uid: s6v28oy3

Introduction The Coronavirus Disease 2019 (COVID19) pandemic has struck Latin America and the Caribbean (LAC) particularly hard. One of the crucial areas in the international community's response relates to accelerating research and knowledge sharing. The aim of this article is to map and characterise the existing empirical research related to COVID-19 in LAC countries and contribute to identify opportunities for strengthening future research. Methods In this scoping review, articles published between December 2019 and 11 November 2020 were selected if they included an empirical component (explicit scientific methods to collect and analyse primary data), LAC population was researched, and the research was about the COVID-19 pandemic, regardless of publication status or language. MEDLINE, EMBASE, LILACS, Scielo, CENTRAL and Epistemonikos were searched. All titles and abstracts, and full texts were screened by two independent reviewers. Data from included studies was extracted by one reviewer and checked by a second independent reviewer. Results 14,406 records were found. After removing duplicates, 5,458 titles and abstracts were screened, of which 2,323 full texts were revised to finally include 1,626 empirical studies. The largest portion of research came from people/population of Brazil (54.6%), Mexico (19.1%), Colombia (11.2%), Argentina (10.4%), Peru (10.3%) and Chile (10%), while Caribbean countries concentrated 15.3%. The methodologies most used were cross-sectional studies (34.7%), simulation models (17.5%) and randomized controlled trials (RCTs) (13.6%). Using a modified version of WHO's COVID-19 Coordinated Global Research Roadmap classification, 54.2% were epidemiological studies, followed by clinical management (22.3%) and candidate therapeutics (12.2%). Government and public funds support were reported in 19.2% of studies, followed by universities or research centres (9%), but 47.5% did not include any funding statement. Conclusion During the first part of the COVID-19 pandemic, LAC countries have contributed to the global research effort primarily with epidemiological studies, with little participation on vaccines research, meaning that this type of knowledge would be imported from elsewhere. Research agendas could be further coordinated aiming to enhance shared self-sufficiency regarding knowledge needs in the region.

The Coronavirus Disease 2019 (COVID19) pandemic has struck Latin America and the Caribbean (LAC) 26 particularly hard. One of the crucial areas in the international community's response relates to accelerating 27 research and knowledge sharing. The aim of this article is to map and characterise the existing empirical research 28 related to COVID-19 in LAC countries and contribute to identify opportunities for strengthening future research. 29

In this scoping review, articles published between December 2019 and 11 November 2020 were selected if they 31 included an empirical component (explicit scientific methods to collect and analyse primary data), LAC 32 population was researched, and the research was about the COVID-19 pandemic, regardless of publication status 33 or language. MEDLINE, EMBASE, LILACS, Scielo, CENTRAL and Epistemonikos were searched. All titles 34 and abstracts, and full texts were screened by two independent reviewers. Data from included studies was 35 extracted by one reviewer and checked by a second independent reviewer. 36

14,406 records were found. After removing duplicates, 5,458 titles and abstracts were screened, of which 2,323 38 full texts were revised to finally include 1,626 empirical studies. The largest portion of research came from 39 people/population of Brazil (54.6%), Mexico (19.1%), Colombia (11.2%), Argentina (10.4%), Peru (10.3%) and 40

Chile (10%), while Caribbean countries concentrated 15.3%. The methodologies most used were cross-sectional 41 studies (34.7%), simulation models (17.5%) and randomized controlled trials (RCTs) (13.6%). Using a modified 42 version of WHO's COVID-19 Coordinated Global Research Roadmap classification, 54.2% were 43 epidemiological studies, followed by clinical management (22.3%) and candidate therapeutics (12.2%). 44

Government and public funds support were reported in 19.2% of studies, followed by universities or research 45 centres (9%), but 47.5% did not include any funding statement. 46

During the first part of the COVID-19 pandemic, LAC countries have contributed to the global research effort 48 primarily with epidemiological studies, with little participation on vaccines research, meaning that this type of 49 knowledge would be imported from elsewhere. Research agendas could be further coordinated aiming to 50 enhance shared self-sufficiency regarding knowledge needs in the region. 51

The Coronavirus Disease 2019 (COVID-19) pandemic has struck Latin America and the Caribbean (LAC) 54 particularly hard, having substantial health, social and economic consequences for the population living in this 55

Region. By mid-July 2021, over 1,300,000 COVID-19 deaths have been reported in the region(1), along with an 56 estimated reduction of 7.4% in gross domestic product (GDP), only in 2020(2). The pandemic seems more 57 difficult to bring under control comparing with other parts of the world, considering that the LAC region has 58 particularly high levels of inequality and labour informality, with comparatively weaker social protection 59 schemes, along with health systems feebly prepared to boost test, track and trace programmes and to face high 60 demand surges for specialised intensive care(3). 61

At the global level, one of the crucial areas in the international community's response to COVID-19 relates to 62 accelerating research, innovation and knowledge translation and sharing(4). On 11 and 12 February 2020, the 63 Global Research Forum, hosted by WHO, developed an initial COVID-19 Global Research Roadmap with two 64 main aims: "1. to facilitate that those affected are promptly diagnosed and receive optimal care; while integrating 65 innovation fully within each research area; and 2. to support research priorities that will lead to the development 66 of sustainable global research platforms that are prepared for the next disease X epidemic"(5). Back then, this 67

Forum identified groups actively researching on COVID19 in Africa, Australia, Europe and North America, but 68 no mention was made of LAC. 69

Despite these global efforts to encourage research collaboration across countries and regions, it is not known if 70 the research that has been conducted in LAC in response to the COVID-19 crisis accounts for the impact that the 71 pandemic is having in the region. A literature review conducted in April 2020 found that only 2.7% of the total 72 publications related to COVID-19 had at least one author with a Latin American-based affiliation(6), showing 73 some insights of the relatively low development of research in LAC at that time. This was corroborated with 74 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. India. The top collaboration partnerships also occurred between these countries, signaling that the LAC region 79

has not significantly participated in COVID-19 research production. 80

Additionally, understanding the development of research during the COVID-19 pandemic becomes especially 81 relevant and necessary as we have seen a "coviditisation" of research(10). This has brought challenges related to 82 redundancy and research waste, leaving other relevant fields unattended, or with a diminished research quality. 83

For instance, a paper evaluating the characteristics and expected strength of evidence of COVID-19 studies 84 registered on ClinicalTrials.gov found that only 29.1% have the potential to result in OCEBM level 2 evidence 85

(good-quality evidence) and that of the randomised clinical trials protocols, only 29.3% are placebo-controlled, 86 blinded studies(11). More recently, we learned that researchers registered more than 2,900 clinical trials related 87 to COVID-19, but the majority were too small or poorly designed, and in some cases there have been an excess 88 of trials for molecules of questionable therapeutic benefit (e.g. hydroxychloroquine)(12). In addition, research 89 funding has also been questioned in terms of the distribution and sources for achieving a fair and sustainable 90 research and development environment(13). In LAC, a study searching for COVID-19 trials on treatment and 91 prevention in the region identified "a trend towards small repetitive non-rigorous studies that duplicate efforts 92 and drain limited resources without producing meaningful conclusions on the safety and efficacy of the 93 interventions being tested"(14). However, apart from this study it is unknown what are the trends of empirical 94 research in LAC during the COVID-19 pandemic, in a context where institutional development for health 95 research has progressed in the region but has been reported as generally uncoordinated and disaggregated, and 96 uneven between countries(15). 97

Considering the large impact that COVID-19 has had in LAC and the relevance of research for the COVID-19 98 response, there is a need to better understand how research production has unfolded in the region to inform 99 contextually relevant decision making. The aim of this article is to map and characterise the existing empirical 100 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint research related to COVID-19 in LAC countries during the pandemic and contribute to identify opportunities for 101 strengthening research for the future. 102

This is a scoping review of the existing empirical research produced in LAC countries related to COVID-19 104 pandemic. 105

Articles in any language were eligible. To be included: 107

• articles needed to be empirical research demonstrated by the report of the scientific methods used to 108 collect and analyze the primary data; 109

• the population being researched must include people from at least one LAC country or their explicit 110 focus is on one or more LAC countries. LAC countries considered are Antigua and Barbuda, Argentina, • the research must be directly or explicitly connected to the current COVID-19 pandemic. 116

Articles were excluded if they: 117

• were any type of evidence synthesis of the literature, or documents building on evidence syntheses (e.g., 118

guidelines, recommendations, consensus, systematic reviews, etc.); 119

• used large international databases and their explicit focus was not in one or more LAC countries; 120

• were not using empirical data to build their findings (including clinical case report). 121

Articles were included regardless of their study design, topic and publication date. Simulation studies were also 122 included if they considered empirical data to build on a specific model (e.g., case counts, tests, etc.). 123 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint

To identify potentially relevant documents, the following bibliographic databases were searched: 125

• MEDLINE and EMBASE using Ovid (December 2019 to 11 November 2020) 126

• LILACS (using VHL) (inception to 11 November 2020) 127

• Scielo (2019 to 11 November 2020) 128

• CENTRAL (2019 to 11 November 2020) 129

• Epistemonikos (2019 to 11 November 2020). 130

To identify grey literature, registry of trials, and pre-print articles, the electronic database search was also 131 supplemented by searching the Living Overview of the Evidence (L-OVE) COVID-19 Repository by the 132 Epistemonikos Foundation, and searching the references of evidence syntheses that were found when assessing 133 the eligibility of the articles. Additionally, registries for studies that are planned to be conducted were 134

complemented with the clinical trials found by Carracedo S et al. 2021(14) . The search strategies that were used 135 in each database are described in the S1 Supporting information 1. 136

Duplicates were removed using EndNote® and Covidence®. All title and abstracts, and full texts were screened 138 by two independent reviewers, resolving disagreements by a third reviewer, or a formal discussion between the 139 two involved reviewers. Covidence ® was used to conduct this process. 140

From the included articles, data was extracted by one reviewer, and was checked by a second independent 142 reviewer, agreeing on what data to extract from each study. The following characteristics of the included studies 143 were extracted (see S1 Supporting information 2 for a complete description of each item extracted): 144

• Lead author, month, year, and citation 145

• Data sources, classified as inert sources, animals, directly humans, databases or documents. 146

• Main objective of the article and research question classified as exposure, prevalence or incidence, 147 benefits and harms of an intervention, prognosis, views and preferences, diagnostic accuracy, or other. 148 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint • Methods and study design of each study, identifying basic sciences, quantitative, qualitative or mixed-149 methods studies. 150

• Type of intervention, exposure, or phenomenon of interest being addressed, using the 9 main research 151 areas outlined by the World Health Organization in their Global Research Roadmap(5), and adding 152 health systems arrangements as one key area. In addition, a "Other" category was added to include 153 topics like the impact of the pandemic in mental health. 154

• Countries of the LAC region where the research is being targeted. 155

• Funding of the study, classified as government and public funds, international organizations, universities 156 or research centres, NGOs, private companies, public private entities, or others. 157

• Journal or website where the study was published. 158

• Status of publication. 159

The data extraction template was piloted with 10 studies by two authors, and the full data extraction process was 160 conducted in Microsoft Excel ®. 161

With the information collected from each study, descriptive information is presented to characterize the research 163 that was being conducted on LAC countries. 164

The total volume of research that was produced by month is presented, and the number of publications per 165 country is analyzed, showing absolute numbers and a rate of publications per population for the countries with 166 more than 1,000,000 inhabitants. Rate per the number of researchers in each country is also calculated, based on 167 the information published by UNESCO(16). The geographical information is presented in interactive maps using 168

Tableau® software. 169

Summaries of the main data sources used, methodologies and study designs, type of research questions and 170 sources of funding are also calculated. 171

Finally, descriptive summaries of the number of publications addressing each one of the modified WHO Global 172

Research Roadmap categories are also presented. 173 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint

Search results 175 14,406 records were found. After removing duplicates, 5,458 titles and abstracts were screened, of which 2,323 176 full texts were revised to finally include 1,626 empirical studies. See Figure 1 for the flow diagram of the review. 177

A full list of included and excluded studies, along with the reasons for exclusion, is provided in the S1 178

Supporting information 3. 179 

In terms of the geographical distribution of the COVID-19 empirical research, all 33 countries in the region had 193 at least one publication conducted in their population. There were 5 articles for which the country was not 194 mentioned, but the authors did mention that they include at least one country from the LAC region. 

Most studies obtained its information directly from humans (54.7%), followed by databases (41.9%). Only 4.2% 211 of studies used documents as data sources and 1.2% used inert sources (e.g. basic science studies). Qualitative 212 methods were used by 4.9% of studies and 3.1% were basic sciences studies. Almost 92% of studies applied 213 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint quantitative methods, with the majority of them using cross-sectional (34.7%), modelling methods (17.5%) and 214

RCTs (13.6%). 221 studies were identified as RCTs of which 207 were ongoing studies at the time of the search. 215

Most research questions were related to exposure, prevalence or incidence (66.4%), followed by benefits and 216 harms of an intervention (21.5%) and prognosis (6.7%). See Table 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. *% sum more than 100% because one article could have more than one category. 220 ** Other include several types of study design such as time series, before-and-after, case-control, and economic 221 evaluations. 222 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. 

The majority of papers that were included in these analyses did not report their funding source (47.5%) or did 233 not have a specific source of funding (21.8%). Governments and the public sector contributed funding to 19.2% 234 of papers, followed by universities and research centres with 9%. NGOs contributed to 2.4% of studies and the 235 private sector to 4.9% (Table 2) . 236 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. involving the collection and analysis of primary data" that would be similar to our definition of "empirical 244 research". In this case, they found 606 studies between December 2019 and December 2020, which would be 245 close to a third of what the present review found for LAC. 246 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. Much of the research production was conducted using observational and simulation methods, with more than 257

half of the publications classified as epidemiological studies, which correlates with the fact that two thirds of 258 papers studied issues related to exposure, prevalence or incidence of COVID-19. Remarkably, 198 studies for 259 candidate therapeutics and only 11 studies exploring candidate vaccines were found, signaling a relatively low 260 participation of LAC population in this type of research. This is more worrying due to the fact that RCTs 261 protocols for such studies have also been found to be of low quality and potential waste of research resources 262 include other important issues such as mental health, which was included separately in our classification. 271 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint Regarding funding sources, close to half of studies (47.5%) did not report their funding provenance. This is 272 higher than what has been reported in previous research, for instance related to health policy and systems 273 research(21) and clinical trials(22) where 31% and 11% of studies, respectively, did not include funding 274 statements. Among the studies that reported funding source, government and public sector sources were the most 275 prevalent, while private sector sources were the least reported. This is also different from the Africa region and simulation studies) and potentially research gaps (e.g. vaccines and therapeutics) to improve collaboration 290 between countries in the region and externally; for instance, to expand networks, to look for and pool funds, to 291 improve surveillance systems, and to boost the production and quality of data and studies(27). There is also a 292 need to build capacity to have more flexible research production in order to act fast in responding to public 293 health emergencies such as pandemics, which can be readily translated to decision making at different levels of 294 health and social systems(28). This seems especially relevant to research linked to existing or developing data 295 systems. Strengthening the data infrastructure has been identified by international organizations such as OECD 296

and WHO/PAHO as essential for managing health systems affected by a pandemic. Having a strong R&D 297 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint infrastructure analysing these data may help to improve the overall quality of data and hence health system 298 performance management. The need for LAC to become more self-sufficient in the production of vaccines, tests, 299 personal protective equipment, and genome sequencing has been recognised(29), and this can be broadened to 300 health system performance management and research capacities, which will be key to make this happen(30). 301

This review has several strengths. Firstly, to our knowledge, this is the first study systematically mapping and 303 characterising all empirical research produced in response to COVID-19 in LAC. Secondly, while most of the 304 studies exploring COVID-19 research production have had a broad bibliometric focus (e.g. counting the total 305 number of publications, not differentiating by their empirical nature), this review only includes empirical studies 306 using at least some basic scientific method that have a higher likelihood of contributing with novel information 307 to literature and decision making. Thirdly, most of the studies exploring countries' involvement in COVID-19 308 research have looked for author's affiliation, as opposed to the actual participation of country's people or 309 population, which is the main focus of this review. Finally, while evidence syntheses often consider certain type 310 of study designs in their inclusion criteria, this review gathers all relevant empirical research, including all type 311 of study designs and methods (e.g., modelling studies, basic science, etc.). 312

Among the limitations of this review, we could only report the month of the studies at the time the searches were 313 conducted, which might have missed some studies that became publicly available later but with earlier dates of 314 publication. Another limitation relates to the possibility that some studies might have not explicitly described the 315 scientific methods used to collect and analyze the primary data, so even if they were empirical, we might have 316 excluded them because of the review criteria. In addition, the UNESCO researcher rate was not available for all 317 the countries, which limited the possibility of including the whole region in the publication rate per researchers 318 ( Figure 3) . Also, although the review did not search directly in trials registries, the databases that were searched 319 actively search all trial registries, such as the LOVE platform and CENTRAL. To make the search even broader, 320 the included studies of Carracedo et al. 2021(14) , which searched thoroughly in such registries, were reviewed 321 and included when relevant. Finally, included studies were not critically appraised in this review, and therefore 322 the quality of research cannot be assessed. 323 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint

During the first part of the COVID-19 pandemic, LAC countries have contributed to the global research effort 325 primarily with epidemiological studies, with little participation on vaccines, meaning that this type of knowledge 326 would be imported from elsewhere. All LAC countries produced COVID-19 empirical research. Research 327 agendas could be further coordinated between different actors within and among LAC countries aiming to 328 enhance shared self-sufficiency to respond to the knowledge needs in the region, especially considering that 329 most of the declared research funding came from public and academic sources. 

The authors have declared that no competing interests exist. Authors hold sole responsibility for the views 344 expressed in the manuscript, which may not necessarily reflect the opinion or policy of the Pan American Health 345

Organization nor the World Bank Group. 346 347 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.07.30.21261386 doi: medRxiv preprint

The author(s) received no specific funding for this work. 349

Latin America and Caribbean's Winding Road to Recovery

Contributions of Latin American researchers in the 363 understanding the novel coronavirus outbreak: A literature review

Mapping the situation of research on coronavirus disease-19 (COVID-19): a 366 preliminary bibliometric analysis during the early stage of the outbreak

Bibliometric analysis of 369 global scientific research on Coronavirus (COVID-19)

Technology and Innovation Outlook 2020: Science and Innovation in Times of 371

Covidization of research: what are the risks

Characteristics and Strength of 376 Evidence of COVID-19 Studies Registered on ClinicalTrials.gov

El panorama de los ensayos 381 clínicos sobre COVID-19 en América Latina y el Caribe: evaluación y desafíos. Revista Panamericana de 382 Salud Pública

moving towards the right direction? Health Res Policy Sys

UNESCO science report: towards 2030

A bibliometric analysis of COVID-19 389 research in Africa

Impact 391 of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). JCO Glob 392 Oncol

Globalization of pediatric research: 394 pharmacological RCTs in Latin America

Adherence to clinical trial registration in 396 countries of Latin America and the Caribbean

The reporting of 398 funding in health policy and systems research: a cross-sectional study. Health Research Policy and 399 Systems

Characteristics 401 of funding of clinical trials: cross-sectional survey and proposed guidance

Advancing health through research partnerships in Latin 404

Gobierno lanza fondo de $2.300 millones para investigación científica sobre COVID19

Soluções Inovadoras para o combate ao COVID-19

COVID-19: Convocatoria

Strengthening 413 institutional capacity for equitable health research: lessons from Latin America and the Caribbean

Research and research 416 capacity strengthening in the context of an emerging epidemic: Zika virus in Latin America

Lancet T. COVID-19 in Latin America-emergency and opportunity. The Lancet

Managing COVID-19 within and 421 across health systems: why we need performance intelligence to coordinate a global response. Health Res 422 Policy Sys